UTRF Licensee Veru, Inc. Announces Positive Results of COVID-19 Therapy’s Phase 3 Clinical Study, Seeking Emergency Use Authorization from FDA
UT Research Foundation licensee Veru, Inc. announced on April 11, 2022, that their Phase 3 clinical trial of sabizabulin as an oral therapy for hospitalized severe COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS) and death showed the drug to be safe and effective. The trial was halted early due to the… Read More